A. Biela

发表

Drug Target Engagement Using Coupled Cellular Thermal Shift Assay—Acoustic Reverse-Phase Protein Array

F. Leroux, B. Déprez, C. Couturier, 2019, SLAS discovery : advancing life sciences R & D.

Discovery of the first Mycobacterium tuberculosis MabA (FabG1) inhibitors through a fragment-based screening.

R. Wintjens, L. Kremer, F. Cantrelle, 2020, European journal of medicinal chemistry.

Controlling Plasma Stability of Hydroxamic Acids: A MedChem Toolbox.

P. Renard, F. Leroux, B. Déprez, 2017, Journal of medicinal chemistry.

Clofoctol inhibits SARS-CoV-2 replication and reduces lung pathology in mice

J. Dubuisson, D. Hober, S. Belouzard, 2021, bioRxiv.

Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology

J. Dubuisson, D. Hober, S. Belouzard, 2021 .

Exploring the Antitubercular Activity of Anthranilic Acid Derivatives: From MabA (FabG1) Inhibition to Intrabacterial Acidification

R. Antoine, F. Cantrelle, A. Baulard, 2023, Pharmaceuticals.

Discovery and Structure-Activity Relationships of N-Aryl 6-Aminoquinoxalines as Potent PFKFB3 Kinase Inhibitors.

M. Jurzak, M. Nowak, M. Kujawa, 2018 .

Optimization of pyridylpiperazine-based inhibitors of the Escherichia coli AcrAB-TolC efflux pump

R. Hartkoorn, F. Leroux, B. Déprez, 2023, European Journal of Medicinal Chemistry.

Clofoctol inhibits SARS-CoV-2 replication and reduces lung pathology in mice

J. Dubuisson, D. Hober, S. Belouzard, 2022, PLoS pathogens.

Beyond the Rule of 5: Impact of PEGylation with Various Polymer Sizes on Pharmacokinetic Properties, Structure-Properties Relationships of mPEGylated Small Agonists of TGR5 Receptor.

B. Staels, F. Gosselet, Geoffroy Dequirez, 2021, Journal of medicinal chemistry.

Discovery, Structure-Activity Relationships, and In Vivo Activity of Dihydropyridone Agonists of the Bile Acid Receptor TGR5.

B. Villoutreix, P. Roussel, B. Staels, 2023, Journal of Medicinal Chemistry.